The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

PROPOFOL Injectable Emulsion, USP (contains benzyl alcohol)

100 mL Single Patient Use, Glass Fliptop Vial

Vial NDC	Carton NDC	Lot Number	Expiration Date	Description	Configuration/Count
0409-4699-54	0409-4699-24	DX9067	01 MAY 2023	1 g/100mL/Single Patient Use, Glass Fliptop Vial	1 Case of 10 Units

*lot may be followed by 01 or 02

Hospira Inc., a Pfizer company, is recalling the above-referenced lot of **Propofol Injectable Emulsion** to the **user level** due to a visible particulate observed in a single vial during annual examination of retain samples**.** Hospira completed a Health Hazard Assessment which concluded that the use of the impacted product presents a remote probability of occurrence for adverse events of limited severity such as fever, malaise, chills, reduced efficacy, and severe adverse events such as sepsis or invasive systemic infections, anaphylaxis, vein irritation, localized vein inflammation or phlebitis, end-organ granuloma or tissue ischemia, pulmonary emboli and infarction. The overall potential risk to patients arising from this issue is considered to be medium. To date, Hospira has not received reports of any adverse events associated with this issue for this lot.